The fragile X syndrome: exploring its molecular basis and seeking a treatment

Expert Reviews in Molecular Medicine
Barbara BardoniEdouard W Khandjian

Abstract

Fragile X syndrome (FXS) - the leading cause of inherited mental retardation - is an X-linked disease caused by loss of expression of the FMR1 (fragile X mental retardation 1) gene. In addition to impairment of higher-cognitive functions, FXS patients show a variety of physical and other mental abnormalities. FMRP, the protein encoded by the FMR1 gene, is thought to play a key role in translation, trafficking and targeting of mRNA in neurons. To better understand FMRP's functions, the protein partners and mRNA targets that interact with FMRP have been sought. These and functional studies have revealed links with processes such as cytoskeleton remodelling via the RhoGTPase pathway and mRNA processing via the RNA interference pathway. In this review, we focus on recent insights into the function of FMRP and speculate on how the absence of FMRP might cause the clinical phenotypes seen in FXS patients. Finally, we explore potential therapies for FXS.

Citations

Nov 23, 2006·Analytical and Bioanalytical Chemistry·Chia-wen K WuJames Eberwine
Oct 6, 2007·Molecular Neurobiology·Maria Vincenza CataniaFerdinando Nicoletti
Jun 6, 2007·Proceedings of the National Academy of Sciences of the United States of America·Meiqin ZhangYingqun Huang
Jan 11, 2008·Proceedings of the National Academy of Sciences of the United States of America·Anna IacoangeliHenri Tiedge
Apr 4, 2007·Nucleic Acids Research·Keizo TakanoYoshihiro Yoneda
Sep 9, 2011·Genome Research·Laetitia DavidovicMarc-Emmanuel Dumas
Jan 27, 2009·PLoS Biology·Elias G BecharaBarbara Bardoni
Dec 17, 2009·PLoS Genetics·Julie B ZangRobert B Darnell
Nov 10, 2013·PLoS Genetics·Alain Y DuryEdouard W Khandjian
Dec 21, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Theodore J PriceFernando Cervero
Jul 21, 2011·Journal of Nucleic Acids·Xin Yan, Robert B Denman
Oct 10, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yolanda de Diego-OteroIgnacio del Arco-Herrera
Jun 24, 2010·Biochimie·Mireille Melko, Barbara Bardoni
Jul 4, 2008·Trends in Genetics : TIG·Kiven E LukongStéphane Richard
Jun 24, 2008·Neurobiology of Disease·Femke M S de VrijRob Willemsen
Jun 26, 2007·Trends in Neurosciences·Charlotte D'Hulst, R Frank Kooy
Oct 19, 2006·Brain Research·Charlotte D'HulstR Frank Kooy
Mar 31, 2011·The FEBS Journal·Ljiljana SjekloćaAnnalisa Pastore
Jun 1, 2013·Developmental Neurobiology·Denise CookKeith K Murai
Jan 19, 2013·Behavioural Brain Research·D OddiS Pietropaolo
Jan 28, 2014·Neuroscience and Biobehavioral Reviews·Thomas MaurinBarbara Bardoni
Sep 12, 2013·Biochemical and Biophysical Research Communications·Xi GongYuping Luo
Feb 15, 2015·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·C M BonaccorsoM V Catania
Nov 23, 2017·Frontiers in Synaptic Neuroscience·Sara CastagnolaThomas Maurin
Dec 23, 2008·Expert Review of Molecular Diagnostics·Christalena SofocleousAriadni Mavrou
Mar 25, 2014·Science China. Life Sciences·HuaLin ZhouJane Y Wu
Aug 1, 2015·Behavioural Pharmacology·Michela ServadioViviana Trezza
Jun 12, 2020·The FEBS Journal·Mohamed S TahaMohammad R Ahmadian
Oct 16, 2018·Frontiers in Molecular Neuroscience·Sara CastagnolaThomas Maurin
Jan 9, 2019·Frontiers in Molecular Biosciences·Thomas Maurin, Barbara Bardoni
Sep 28, 2007·Molecular Biology Reports·Kanchan Singh, S Prasad

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.